Chronic hepatitis C: treat or wait? A prospective study on reasons for treatment or nontreatment in the era of first-generation protease inhibitors.

摘要: BACKGROUND AND AIMS: In many countries, current treatment for patients with chronic hepatitis C involves a combination of peginterferon and ribavirin, associated protease inhibitor virus genotype 1. More recent efficient less toxic antiviral treatments are now available some patients. Thus, the decision to treat or wait is challenging. The aims this study were to: (a) estimate proportion treated patients, (b) evaluate reasons decision, (c) examine patients' points-of-view in decision. METHODS: This was prospective conducted at three French referral centers between March June 2013. Epidemiological virological data, nontreatment, data on doctors' choices collected. RESULTS: A total 255 analyzed. Only 52.6% fibrosis 2 higher treated. Treatment uptake reduced following groups: previously those poor tolerance during prior treatment, heavy alcohol consumption, hepatocellular carcinoma. Of cirrhotic 55% not treated: 51.1% had contraindication, 22.2% previous nonresponse. When refused by patient, fear side effects professional problems most frequently cited (90 40%, respectively). CONCLUSION: Patients primarily according consensus guidelines. However, only 45% 7.6% cases, patient therapy. enabled us measure importance choice medical decision-making. Well-informed expected more but also well-tolerated therapy